{
  "metadata": {
    "inference_mode": "ollama",
    "ollama_model": "als-lm-500m:f16",
    "ollama_url": "http://localhost:11434",
    "model_name": "als-lm-500m:f16",
    "generation_params": {
      "max_tokens": 512,
      "temperature": 0.0
    },
    "benchmark_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/questions.json",
    "timestamp": "2026-02-28T07:46:30.893853+00:00",
    "total_questions": 160
  },
  "responses": [
    {
      "question_id": "DRUG-001",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the FDA-approved drugs for ALS treatment and when they were approved.",
      "response": "\n\n\nThe study, we used a comprehensive research. The study, we identified a single-based approach to identify the potential of the future research.\n\n\n\n",
      "tokens_generated": 36,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-002",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how riluzole works to treat ALS at the molecular level.",
      "response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43) and RNA sequencing. We performed the RNA sequencing.\n\n\n\n\n\nthe RNA sequencing\nThe RNA-binding protein-specific RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we used a single-type RNA-length RNA-seq. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5). The RNA-43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\n\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-003",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the mechanism of action of edaravone (Radicava) in ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the brain, and the brain, and the brain, and the brain, and the brain, and the brain. The brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have been reported that the brain, we have a role in the brain, we have a role in the brain, we observed in the brain.\n\n\n\n\nand the molecular changes in the brain and the brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed in the brain. We also present study, we have a role in the brain and the brain, we found that the brain, we identified a significant differences between the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed that the brain.\n\n\n\n\n\n\n\n\nand the brain and the brain, we found that the brain, we identified a significant differences in the brain, we investigated the brain, we performed the brain, we used the brain, we examined the brain, we have a single-specific gene expression of the RNA sequencing (43) and RNA-binding protein. We found that the RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-004",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Name the drug prescribed for pseudobulbar affect (uncontrollable laughing or crying) in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-005",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the role of baclofen in managing ALS symptoms.",
      "response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the importance of the disease progression of the disease.\n\n\n\n\n\n, we have been identified a common genetic changes in the disease. We have a role in the most common genetic mutations in the disease.\n\n\n\n\n, we have a rare neurodegenerative diseases, we have been reported that the disease, we have a role in the disease progression of the disease.\n\n, we have also be associated with the disease, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n,\n,\n,\n,\n, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-006",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the results of the Bensimon et al. pivotal trial of riluzole in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a significant differences between the role in the importance of the disease progression. We found that the most common genetic changes in the disease. The most common mutations in the most common mechanisms of the disease.\n\n\n\n\n\n\n\nand the most common mutations in the most common genetic variants in the most common proteins, we have a common pathways, we identified in the ALS.\n\n\n\n\n\nand the most common mutations in the most common proteins, we investigated the molecular and RNA-binding protein (43) and RNA-associated TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-007",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe tofersen, its mechanism, and the specific ALS patient population it targets.",
      "response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role in the role in the role in the role in the role in the role in the role in the role in the role in the role of the pathogenesis of the importance of the underlying mechanisms, we have a role in the development of the disease. The most common mutations in the disease progression of the disease, we identified a rare diseases, we have been reported that the disease, we found that the disease, we have a common genetic and disease, we have a common genetic changes in the disease, we have a common mechanisms, and FTD.\n\n\n\n\nand the most common mutations in AD, we have a role of tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau pathology in AD, and tau pathology, and tau pathology, tau pathology, tau, and tau, tau aggregation, and tau, and tau, and tau pathology, and tau, tau, tau, tau, tau, and tau, and tau, and tau pathology, tau, tau pathology, tau, tau, tau, and tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-008",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the common adverse effects associated with riluzole use in ALS patients.",
      "response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a recent study, we investigated the role of tau pathology in the tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\nand tau is a common tau aggregation of tau aggregation of tau and tau pathology, we found that tau aggregation of tau pathology in the tau aggregation of tau aggregation of tau aggregation of tau pathology in AD, which are associated with tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology. The study, we have a role in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology in AD, which is associated with tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology in the tau pathology in the tau plaques, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology.\n\nand tau pathology in the tau aggregation of tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology in the tau pathology.\nand the aggregation of tau pathology, we found that tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology, which is a role in the",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-009",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe AMX0035 (Relyvrio) and the results of the CENTAUR clinical trial for ALS.",
      "response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the disease progression and disease progression of the disease.\nand the most common genetic mutations in the disease, we have a rare diseases, we have been identified in the disease. We have a significant differences between the most common genetic changes in the disease, we found that the disease, we have a more common variants in the disease.\n\n\n\n, we have a role of the most common genetic variants in the most common mutations in the most common genetic and FTD, we identified in AD pathology, we observed in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, and tau pathology. We found that tau pathology, we have a role of tau pathology, we investigated the aggregation, we show that tau pathology in AD pathology, we identified in AD, we observed in AD pathology, we have been reported that tau pathology in AD pathology in AD, and tau pathology in AD pathology, tau pathology in AD, and tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology, we observed in AD pathology.\n\nand the most common tau pathology in AD, we investigated the aggregation of tau pathology, we found that tau pathology, we have a role in AD pathology, we identified in AD pathology in AD pathology and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology.\n\nand tau pathology, we have shown that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we found that tau pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology, and tau pathology, tau pathology, tau pathology. We have been identified a role in AD pathology in AD pathology in AD pathology in AD, we investigated the aggregation of tau pathology in AD pathology, we have been shown that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD pathology, tau pathology, and tau pathology in AD",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-010",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe masitinib and explain how it is proposed to help in ALS treatment.",
      "response": "\n\n\nThe study, we have a recent study, we found that the first study, we identified a significant differences in the disease progression of AD pathology. The most common tau pathology in AD patients with AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau plaques, tau, and tau, tau, tau, and tau, tau, and tau, tau, and tau, tau pathology, tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-001",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Identify the most frequently mutated gene in familial ALS cases.",
      "response": "\n\n\n\n\n, we have a rare disease. We found that the most common genetic and FTD.\n\n\n\nThe most common variant in the most common mutations in the most common protein in the tau pathology in the tau aggregation of tau pathology. The tau is also known to be associated with the tau pathology, which are the tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation, and tau pathology.\n\n\n\nand tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation in the tau aggregation of tau aggregation, and tau aggregation, and tau aggregation of tau aggregation, and tau aggregation, which is a common tau pathology.\n\n\n\n\n, we have been identified by the aggregation of tau pathology in the tau aggregation of tau aggregation of tau pathology in AD, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, which are known to be associated with tau pathology.\n\nand tau pathology, we have been identified by the tau plaques, we investigated the aggregation of tau pathology in AD pathology in the aggregation of tau pathology in the tau pathology in the aggregation of tau pathology in the aggregation of tau pathology. We found that the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology, we investigated the tau pathology in the tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\n\nand the aggregation of tau pathology is a role in the aggregation of tau pathology in the aggregation of tau pathology in the aggregation of tau pathology, which is a common tau pathology and tau pathology. We have been identified in AD pathology, we investigated the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology.\n\n\nand the most common tau pathology, we have a role of tau aggregation of tau pathology, which is a common tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology.\nand the tau pathology is a recent study",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-002",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the role of SOD1 mutations in ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the ALS patients with SMA patients with SMA patients. We found that the ALS patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients.\n\n\n\n\n, we have a rare disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-003",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the TARDBP gene, its protein product, and its role in ALS.",
      "response": "\n\n\n\nThe most common variant of the RNA-43, and tau aggregation, and tau pathology, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau-43, and tau, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau pathology.\n\n\n\n\n\nThe most common mutations in AD, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-004",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the function of FUS and how FUS mutations lead to ALS.",
      "response": "\n\n\n\n\n\n, we have a rare disease. We found that the most common TDP-43 pathology in the TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-005",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the proportion of ALS cases that are familial (inherited) versus sporadic.",
      "response": "\n\n\n\n\n\n\nThe study, we used to evaluate the role in the disease progression and disease progression.\n\n\n\n\n\n, we have a significant differences between the disease, and FTD, and AD, and tau pathology, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-006",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe TBK1 and explain its connection to ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression. We have a common genetic mutations in AD pathology. The most common tau aggregation of tau pathology in AD pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-007",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the molecular mechanisms by which the C9orf72 hexanucleotide repeat expansion causes ALS.",
      "response": "\n\n\n\n\nThe most common in the SMN protein and FUS, and FUS, and FUS, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-008",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Name the protein product of the SOD1 gene and describe its normal function.",
      "response": "\n\n\n\n\n\n\nand the RNA-binding protein, which is a protein. The RNA-binding protein (Fig. 5).\n\n\na is the RNA-binding protein (Fig. 5A) is a protein in the RNA-binding protein (Fig. 5B).\n\n\n\n\n\n\nthe RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein, which is the RNA-binding protein (Fig. 5). The RNA-binding protein (Fig. 5C) is a protein in the RNA-binding protein (Fig. 5B) is the RNA-binding protein (Fig. 5-43 and the RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein (Fig. 5).\n\n\n\n\n\n\nand the RNA-binding protein, which is a protein in the RNA-binding protein (Fig. 5). The RNA-binding protein (Fig. 5B) and the RNA-binding protein (Fig. 5A) is also known to the RNA-43 (Fig. 5C) is the RNA-binding protein (Fig. 5A) is the RNA-binding protein (Fig. 5A) is a protein in the RNA-binding protein (Fig. 5B) and the RNA-binding protein (Fig. 5D).\n\n\n\n\n\n\nand the RNA-binding protein (Fig. 5C) is also known to the RNA-43, which is the RNA-binding protein (Fig. 5A) is a protein (Fig. 5-43-43-43 (Fig. 5B), and the RNA-43-binding protein (Fig. 5-43 (Fig. 5).\n\nand the RNA-binding protein (Fig. 5C) is the RNA-binding protein (Fig. 5-43, which is a protein in the RNA-43-43 (Fig. 5A) is the RNA-binding protein (Fig. 5B), and the RNA-binding protein (Fig. 5-43-43-43-43-43-43-43-43-43-43-43-43-43, and the RNA-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (Fig. 5A) is a protein (Fig. 5-43-43-43-43-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-009",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the function of BRCA3 and its contribution to ALS.",
      "response": "\n\n\n\n\n\n\n\n\nThe study, we investigated the study, we conducted a comprehensive studies, we have been identified in the clinical trials.\n\n\n\n\n\n\n\n\n\n, we have a recent study, we have a comprehensive research that the study, we have a comprehensive research on the study, we have been developed a comprehensive research.\n\n\n\n\nThe study, we have been identified in this study, we have been identified a comprehensive studies, we have a comprehensive research that the study, we have a comprehensive research, we have a comprehensive research.\n",
      "tokens_generated": 122,
      "is_coherent": true
    },
    {
      "question_id": "GENE-010",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the genetic overlap between ALS and frontotemporal dementia (FTD).",
      "response": "\n\n\n\n\n\n\n\n, we investigated the disease progression of the disease. We have a role in the disease progression of the disease progression of the disease.\n\n\nThe most common neurodegenerative diseases, we identified a rare neurodegenerative diseases, and disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-001",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the El Escorial diagnostic criteria for ALS and its classification levels.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-002",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare the Awaji-shima criteria with the revised El Escorial criteria for ALS diagnosis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-003",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the clinical signs of upper motor neuron involvement in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n, and other cases, and are associated with SMA, and FTD, and FTD, and FTD, and FTD.\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-004",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the clinical signs of lower motor neuron involvement in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-005",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the electromyography (EMG) findings typically seen in ALS patients.",
      "response": "\n\n, we investigated the study of the study. We found that the study, we have a significant differences between the disease. The results of the most common genetic changes in the disease progression and FTD.\n\n\nThe most common genetic mutations in the most common variants in the disease progression of AD pathology, and tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-006",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the Gold Coast criteria and how they simplify ALS diagnosis compared to earlier criteria.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the disease progression of the disease.\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n\n\n, we have a rare neurodegenerative diseases, we have a common genetic and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau pathology, and tau, and tau, and tau, and tau, tau, and tau, tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-007",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the key conditions that must be ruled out when diagnosing ALS.",
      "response": "\n\n\n\n\n\n\n\nThe study, we have a significant differences in the disease progression of the disease.\n\n\n\n\n, we found that the most common genetic mutations in the disease. We also associated with the most common variants in the disease and the disease.\n\n\n\n\n\nand the most common TDP-43, we identified a TDP-43, we have a TDP-43, we investigated the TDP-43 pathology in the TDP-43, we found that TDP-43 aggregation of TDP-43, we observed in the TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-008",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe Kennedy disease and explain how it is distinguished from ALS.",
      "response": "\n\n\n\n\nThe study, we have a common genetic and in the disease.\n\n\n\n\n\n\n, we investigated the most common genetic changes in the underlying mechanisms of the development of the disease progression.\n\n\n\n\nand the role in the disease, we have been identified in the disease, we found that the disease.\n\n\n, we have a rare neurodegenerative diseases, we have a common genetic mutations in the disease. We have a common genetic and FTD, we have a common genetic mutations in AD pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau pathology, and tau aggregation, and tau, and tau, and tau, and tau, and tau pathology.\nand the tau pathology, we have a common tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-009",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the Brainbridge classification system for ALS diagnostic subtypes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-010",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the average diagnostic delay from first symptoms to confirmed ALS diagnosis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-001",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the ALSFRS-R scale and explain its role in ALS clinical trials.",
      "response": "\n\n\n\n\n\nThe study, we investigated the study, we conducted a comprehensive studies, we have been identified a comprehensive research. The study, we used to identify the importance of the potential for the future research.\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive research on the clinical trials, we have a comprehensive research, we have a comprehensive research and clinical trials, we have been developed a comprehensive research.\n\n\n\nThe study, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research, we identified in the study, we have a comprehensive research. The study, we have a comprehensive research that the study, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research on the study, we have been developed a comprehensive research.\n\n",
      "tokens_generated": 182,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-002",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the VALOR trial design for tofersen in SOD1-ALS and its key results.",
      "response": "\n\n\n\n\nThe study, we investigated the first study, we used a comprehensive studies. We have a comprehensive research that the clinical trials, we have been identified a comprehensive research. The study, we have demonstrated that the potential of the importance of the development of the development of the development of the development and clinical trials.\n\n\n\n\nThe authors have shown that the use of the limitations, we have a promising therapeutic interventions for the need to the treatment in the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n\n\n\nThe study, we have been identified a comprehensive research on the use of the clinical trials, and clinical trials, we have demonstrated that the need for the importance of the potential in the treatment.\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research.\nThe study, we have a comprehensive research on the use of the current research and clinical trials, we have a comprehensive research.\n\n\n\n",
      "tokens_generated": 244,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-003",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List and explain the primary efficacy endpoints typically used in ALS clinical trials.",
      "response": "\n\n\n\n\n\n\nThe study, we have a comprehensive research that the study, we have a single-based approach for the use of the future research.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have been identified in the study. The study, we have a recent study, we used a comprehensive and clinical trials, we will be available in the study.\n",
      "tokens_generated": 96,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-004",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the clinical trial that resulted in riluzole being approved for ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-005",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the key Phase 3 clinical trial of edaravone for ALS and its results.",
      "response": "\n\n\n\n\nThe study, we investigated the study, we have a comprehensive studies. We have been identified in the study, we have not be used to identify the importance of ALS.\n\n\n\n\n\nand the study, we have a single-based approach for ALS. The study, we have a single-based clinical trials, and ALS, we have a comprehensive research.\n",
      "tokens_generated": 82,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-006",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the platform trial concept and describe its application in ALS clinical research.",
      "response": "\n\n\n\n\n\n\n\n\n\nThe study, we identified a comprehensive research that the first study of the study. The study, we have been reported that the most common genetic diagnosis of the disease progression.\n\n\n\n\n\n\n, we have a recent study, we investigated the role of the importance of the clinical trials for the development of the need to identify the future research.\n\n\n\n\n\n\nand the current studies, we have a comprehensive and clinical trials, we have been identified in the disease progression of the disease.\n\n\n\n\n\n\n, we have been developed a comprehensive research on the study, we have a comprehensive research. We have a comprehensive research that the study, we have a comprehensive research on the study, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive understanding of the clinical trials for the study, we will be available in the future research.\n\n\n\n\n\n\n",
      "tokens_generated": 201,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-007",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the outcomes of NCT09876543 studying neuromax for ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-008",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain what ClinicalTrials.gov is and its role in ALS clinical research.",
      "response": "\n\n\n\n\nThe study, we have been reported that the importance of the development of the disease progression of the disease. The most common genetic mutations in the disease.\n\n\n\n\n\nand the most common genetic variants in the most common mechanisms, we have a rare diseases, we have been identified in the disease.\n\n\n\n\nThe most common genetic and genetic mutations in the disease, we have been identified in the disease, we have a common genetic mutations in the disease. The most common genetic variant in the most common genetic variants in the disease, we have a common genetic mutations in the disease, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, we have a common genetic and FTD, we have been identified in the disease.\n\n\n\n\n\nThe most common genetic mutations in the disease, we have a rare neurodegenerative disease, we have a rare neurodegenerative disease, we have been reported that are associated with AD, and tau pathology, and tau, and tau, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-009",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the main challenges that complicate the design and execution of ALS clinical trials.",
      "response": "\n\n\n\n\n\nThe study, we identified a comprehensive research on the importance of the development of ALS.\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the disease progression of ALS.\n, we found that the most common genetic mutations in the disease.\n\n, we have a rare neurodegenerative diseases, we have a common genetic and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-010",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain how neurofilament light chain (NfL) is used as a biomarker in ALS clinical trials.",
      "response": "\n\n\n\nThe study, we have been reported that the first study of the most common genetic variants in the disease. The most common genetic mutations in the most common in the most common mutations in the disease progression of the disease.\n\n\n\n\n\n, we investigated the most common genetic changes in the molecular mechanisms for the role in the development of the disease progression and disease progression, we have a common pathways, we identified a common disease. We have been reported that the disease, we have not be associated with the disease.\n\n\n\n\nand the most common mutations in the disease, we have a rare neurodegenerative diseases, we have a common genetic changes in the disease, we have a common disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD. We found that the most common genetic mutations in AD, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-001",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the concept of excitotoxicity and its role in ALS motor neuron death.",
      "response": "\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "MECH-002",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe TDP-43 pathology and explain why it is considered a hallmark of ALS.",
      "response": "\n\n\n\n\nThe most common genetic diagnosis, with the disease, and FTD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer-ALS, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-003",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of oxidative stress in ALS pathogenesis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\nThe study, we investigated the potential of the role in the development of ALS.\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the role in the disease progression of the disease.\n, we found that the most common genetic and ALS.\n\n, we have a significant differences between the most common mutations in the disease. We have a rare neurodegenerative diseases, we identified a common genetic changes in the disease.\n\n\n\n, we have been reported that the most common genetic diagnosis of the disease, we have a common genetic mutations in the disease.\n\n\n\n, we investigated the role for the disease, we have a common genetic and FTD, we have a rare neurodegenerative diseases, we identified a common genetic and disease progression, we have a common genetic changes in the disease. We found that the most common genetic mutations in the disease, we have been reported that the disease, we have a common genetic variants of the disease, we have a common genetic mutations in the disease, with a rare neurodegenerative diseases, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n\n\n\n\n, we identified a common genetic diagnosis of AD, we have been reported that are known to be associated with a common neurodegenerative diseases, and FTD.\n\n\n, we have a rare neurodegenerative disease, we have a common genetic mutations in the most common genetic and FTD, we have a common genetic and FTD, and FTD, and tau pathology, and tau pathology, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-004",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain what protein aggregation means in the context of ALS and which proteins are involved.",
      "response": "\n\n\n, we have a role of the disease progression of AD. The most common mechanisms that the development of tau pathology in AD.\n\nand the aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation and tau aggregation of tau aggregation, and tau aggregation of tau aggregation, and tau aggregation, which is known to be associated with tau aggregation.\n\n\n\n\n\n, we have been identified a role in AD, we investigated the aggregation of A\u03b2-associated tau pathology. We found that the aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation and tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation in AD.\n\n\n\nand tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau pathology, we found that the aggregation of tau aggregation of tau aggregation of tau aggregation of tau pathology in AD, which is a role in AD and tau pathology in AD, and tau pathology in AD, and tau pathology in AD, and tau pathology.\n\n\n\nand tau-43 aggregation of tau pathology in AD, we investigated the aggregation of A\u03b2-associated tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD. We have been identified by the aggregation of tau pathology in AD, we found that tau pathology in AD, we show a role in AD and tau pathology in AD pathology in AD pathology in AD pathology in AD, which is a role in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology.\n\nand the most common tau aggregation of tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau aggregation, tau, tau, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-005",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the contribution of non-neuronal glial cells to ALS disease progression.",
      "response": "\n\n\n\nThe most common in the most common in the disease, and FTD, and AD, and PD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-006",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how defects in RNA processing contribute to ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the potential of the role in the development of the disease progression and disease.\n\n\n\n\n\nThe most common mutations in the molecular modifications, we have been identified a novel mechanisms that are essential for the aggregation of the cellular homeostasis.\n\n\n\nand the RNA-binding protein (43) is a complex, which is a crucial for the RNA-associated proteins, which is a role in the RNA-binding protein.\n\n\n\n\n\n\n\n\n\n\nand the RNA-binding protein, we have a common RNA-binding protein, we investigated the RNA-binding protein-binding protein-binding protein (Figure 5). The RNA-43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein in the RNA-binding protein-binding protein.\nand the RNA-binding protein-binding protein-binding protein (Figure 5A) and RNA-binding protein (Figure 5B, we identified a protein (Figure 5). The RNA-43-associated TDP-43-43-43 aggregation of TDP-43, we found that TDP-43-43 aggregation in the TDP-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, we found that TDP-43-43 aggregation of TDP-43-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, we found that TDP-43-43-43-43 aggregation of TDP-43-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 aggregation in the TDP-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-007",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of autophagy dysfunction in ALS pathogenesis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the role in the role in the role in the role in the disease progression of the disease.\n\n\n\n\n\n\n, we have a common mechanisms underlying mechanisms of the pathogenesis of ALS.\n, we found that the most common mutations in the most common proteins, and ALS.\n, we identified a novel mechanisms of ALS. We have a recent study, we investigated the role of the importance of the potential for ALS.\n\n\nand the molecular modifications, we have been identified a crucial role in the development of ALS.\n, we found that the ALS, we have a common proteins, we have a significant increase in the most common mutations in the disease progression of ALS. We have a result in the ALS, we investigated the ALS and ALS, we found that the ALS, we found that the ALS, we identified a role in the ALS.\n\n, we have a role of ALS, we have a role in the ALS, we have a significant differences in the disease progression of the most common mutations in the disease. We have a result in the disease, we investigated the disease and FTD, we found that the disease progression of the disease progression of the disease progression of AD pathology in the disease.\n\n\n\n, we identified a role in the disease, we have been reported that the disease, we have a common tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology in the tau pathology in AD. We found that the most common tau pathology in AD pathology in AD pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology, we have a role of tau pathology in AD pathology in AD.\n\nand tau pathology, we identified a recent study, we have a role of tau pathology, we found that tau pathology in AD and tau pathology in AD, we investigated the aggregation of tau pathology in AD. We found that the tau pathology in AD, we found that tau pathology in AD, we found that tau pathology in AD pathology in AD pathology in AD, we identified a common tau pathology in AD pathology in AD pathology in AD pathology in AD pathology and tau pathology, which is a role in AD pathology in AD.\n\n\n\nand the aggregation of tau pathology in AD pathology in AD, we have been reported that tau pathology, we found that tau pathology in",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-008",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how SOD1 protein misfolding leads to motor neuron damage in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "MECH-009",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the role of neuroinflammation in ALS disease progression.",
      "response": "\n\n\n\n\n, we investigated the most common mechanisms of the pathogenesis of the disease.\n\n\n\n\n\n\n\n\n\n, we have been identified a common mechanisms that the disease.\n\n, we found that the most common genetic and the disease, we have a role in the disease.\n\n\nand the disease is a rare neurodegenerative diseases, we have a common genetic mutations in the disease progression of the disease.\n\n\n\n, we have a recent study, we investigated the underlying mechanisms of the development of the disease. We have been identified a novel insights into the disease and clinical trials, we have a comprehensive research on the importance of the disease.\n\n\n\n\n\n\n, we have demonstrated that the role in the need for the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the disease.\n\n\n\n\nand the importance of the development of the role in the disease progression of the disease, we have been identified in the disease.\n\n\n\n, we have a rare neurodegenerative diseases, and disease, and FTD, and Alzheimer's disease, and frontotemporal dementia, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-010",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the PLK4 kinase signaling cascade in ALS motor neuron degeneration.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-001",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year riluzole received FDA approval for treating ALS.",
      "response": "\n\n\n\n\n\n\n\n\n, we conducted a single-based sequencing (1) and RNA-43 (43 (43), and FUS (43 (43) and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-002",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year edaravone (Radicava) received FDA approval for ALS treatment.",
      "response": "\n\n\n\nThe study, we used the study. The study, we conducted a single-based data collection, and the data, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\nThe study, we performed the study, we used the data from the data, we used the data, we used the data, we used the data, we identified a comprehensive studies. We have a comprehensive data, we used the data, we conducted a comprehensive and the data, we used to evaluate the data. The study, we have a comprehensive data, we performed the data, we used the data, we used the data from the data, we used for the data, we identified a comprehensive data, we used the data, we used the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive information, we have a comprehensive studies, we have a comprehensive and the data, we have a comprehensive data, we have a comprehensive research on the data, we have a comprehensive data. We used the data from the data, we will be available in the data, we will be performed using the study, we will be used to evaluate the data.\n\n\n",
      "tokens_generated": 263,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-003",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when ALS was first clinically described and by whom.",
      "response": "\n\nThe study, we have a significant differences in the disease progression of AD pathology.\n\n\n, we found that the most common tau pathology in AD patients with AD pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, tau, tau aggregation, and tau, and tau, and tau pathology, and tau pathology.\n\n\nand tau pathology, we found that the tau pathology in AD pathology in AD patients with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau pathology, tau, tau, tau aggregation, tau, tau, and tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-004",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the year SOD1 mutations were first identified as a cause of familial ALS.",
      "response": "\n\n\n\n\n\nThe study, we investigated the study, we performed the study, we conducted in the study, we used the study, we analyzed the study, we have a single-based sequencing. We used the first study, we used the data from the data, we identified a comprehensive studies. The study, we identified a single-specific RNA-seq and RNA-binding protein (43) and RNA-type RNA-binding protein in the RNA-binding protein (43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (43) and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-005",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when the C9orf72 hexanucleotide repeat expansion was identified as a genetic cause of ALS.",
      "response": "\n\n\n\n\nThe study, we found that the disease progression in the disease. We have a significant difference between the most common variant in the disease. The results from the most common variants in the disease and the disease.\n\n\n\n\n\n\nand the first study, we identified a single-specific RNA sequencing (43) and FUS (43, and tau pathology, tau aggregation, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-006",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain when and why ALS became known as Lou Gehrig's disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-007",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Provide the dates of the original El Escorial criteria and their major revisions.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the impact on the importance of the development of the context of the use of the patient.\n\n\n\n\n, we have been reported that the most common genetic changes in the disease.\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative diseases, and the disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-008",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when the Ice Bucket Challenge occurred and its impact on ALS research.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-009",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when the ALSFRS-R was developed and explain how it improved upon the original ALSFRS.",
      "response": "\n\n\n\nThe study, we conducted a comprehensive data from the study. The study, we used the study, we identified a comprehensive studies, we have a comprehensive research that the data, we have a comprehensive data. We have a comprehensive analysis of the data, we have been reported that the data, we have a significant correlation between the data, we have a more common and clinical trials, we have a comprehensive data.\n\n\n\n\n\n\nThe study, we identified a comprehensive studies, we used a comprehensive research on the data, we have a comprehensive data from the data, we have a comprehensive analysis of the data, we have a comprehensive studies, we have a comprehensive data, we will be available in the data. We have a comprehensive and clinical trials, we have a comprehensive study, we have a comprehensive data, we have been identified a comprehensive research on the data, we have a comprehensive research.\n\n\n\n",
      "tokens_generated": 191,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-010",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Determine whether riluzole received FDA approval for ALS treatment in 2005.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-001",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the approximate global incidence rate of ALS.",
      "response": "\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-002",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the average age at which ALS symptoms typically begin.",
      "response": "\n\n\nThe study, we used a single-based approach for the model. The data were performed using the data from the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{wasysym}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{wasysym}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-003",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the male-to-female ratio in ALS and whether it differs by disease subtype.",
      "response": "\n\n\nThe study, we investigated the study, we identified a comprehensive studies, we have been reported that the clinical trials. We have demonstrated that the importance of the potential for the future research.\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive research on the study, we have a comprehensive studies, we have identified a comprehensive and clinical trials, we have been developed a comprehensive research. The study, we have a comprehensive research that the study, we have a comprehensive research, we have a comprehensive understanding of the study, we have a comprehensive research.\n\n",
      "tokens_generated": 131,
      "is_coherent": true
    },
    {
      "question_id": "EPI-004",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the median survival time from symptom onset and from diagnosis for ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-005",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the unusually high ALS prevalence historically observed in Guam and its implications.",
      "response": "\n\n\n\n\n\n\n, we have a role in the use of the treatment.\n\n\n\nThe study, we investigated the study, we found that the study, we have a significant differences between the impact on the importance of the potential for the importance of the importance of the importance of the importance of the development of the importance of the importance of the context of the role in the importance of the importance.\n\n\n\n\n\n\n\n\n\nThe study, we have a role in the study, we investigated the study, we have a comprehensive studies, we have been identified a comprehensive research. We have a comprehensive studies, we have a significant differences between the data from the first-based approaches for the data, we have a comprehensive and clinical trials. The study, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research.\n\n\n\n\nThe study, we have a comprehensive research, we have been identified in the study, we have a comprehensive research. We have a comprehensive studies, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research and clinical trials, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have been identified in the data, and to evaluate the importance of the need for future research.\n\n",
      "tokens_generated": 283,
      "is_coherent": true
    },
    {
      "question_id": "EPI-006",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the environmental and lifestyle factors that have been linked to increased ALS risk.",
      "response": "\n\n\n\nThe most common mechanisms of the development of the disease, such as a common genetic mutations in the disease.\n\n\n\n\n\n\n\n\n\n\nand the most common genetic mutations,\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-007",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence regarding ALS risk in professional athletes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-008",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the two primary clinical presentations of ALS based on where symptoms first appear.",
      "response": "\n\n\n\n\n\n, we investigated the study, we identified a comprehensive studies, we have been reported that the disease progression of the disease.\n\n\n\n\n, we found that the most common genetic and the disease, we have a role in the disease.\n\n\n\n\n, we have a recent study, we have a significant correlation between the first study, we identified a comprehensive studies, we have a comprehensive research on the clinical trials. We have a comprehensive research on the current research, we have been developed a comprehensive and clinical trials.\n\n\n\n",
      "tokens_generated": 118,
      "is_coherent": true
    },
    {
      "question_id": "EPI-009",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence linking military service in the Gulf War to increased ALS risk.",
      "response": "\n\n\n\n\n* P.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 2,
      "is_coherent": false
    },
    {
      "question_id": "EPI-010",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the epidemiological evidence for the ALS cluster among Faroe Islands fishing communities.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-001",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the criteria and guidelines for starting non-invasive ventilation (NIV) in ALS patients.",
      "response": "\n\n\nThe study, we have a study, we found that the study, we used to evaluate the need for the importance of the future research.\n\n\n\n\n\n\nThe study, we conducted a comprehensive studies, we identified a comprehensive and clinical trials, we have been developed a comprehensive understanding of ALS. We have a comprehensive research on the study, we have been identified in the study, we have been used to identify the need for AD.\n\n\n\n\n",
      "tokens_generated": 99,
      "is_coherent": true
    },
    {
      "question_id": "CARE-002",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the indications and timing for PEG tube placement in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-003",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the multidisciplinary approach to ALS care and its benefits.",
      "response": "\n\n\n\n\n\n\n\n\n\nThe study, we identified a comprehensive research.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been reported that the role of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\nThe study is a recent study, we have a comprehensive research on the current and clinical trials.\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been developed the use of the need to identify the importance of the future research.\n\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive studies, we have identified a comprehensive research on the data from the data and clinical trials, we have a comprehensive research.\n\nand the study, we have been developed the data, we have a comprehensive research.\n\n\n\n, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we will be available in the literature.\n\n\n\n\n\n\n\nThe study, we have a systematic review, we have a comprehensive studies, we have been developed the data from the study, and clinical trials for the study, and the study, and to evaluate the importance of the need for future research.\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive research on the literature, we will be available in this study.\n\n\n\nThe study, we have been developed a comprehensive data, we will be used to identify the data.\n\n",
      "tokens_generated": 352,
      "is_coherent": true
    },
    {
      "question_id": "CARE-004",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the communication aids and assistive technology used by ALS patients who lose speech.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-005",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Discuss the decision-making around tracheostomy and long-term mechanical ventilation in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-006",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how physical therapy helps ALS patients manage their symptoms.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-007",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the palliative care strategies employed for ALS patients in the terminal phase.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-008",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the treatment options for excessive saliva (sialorrhea) in ALS patients.",
      "response": "\n\n\n\n\nThe study, we conducted a cohort of the first study. The study was performed using the study, and the study, and the study, and the study, and the study, and the study, and the study, and the study, and the study, and the study, and the study, and ALS patients with a disease, and AD, and AD, and tau pathology.\n\n\nThe study, we identified a comprehensive research on the clinical trials, we have been identified in AD. The study, we have previously reported that the clinical trials, we have a significant correlation between AD, and AD pathology in AD, and AD, and AD, and AD, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\n\nand the most common clinical trials, we have been identified a comprehensive research on the study, we have identified in AD, we have been reported that the AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, tau pathology. We found that the AD patients with AD, we have a significant correlation between AD, AD, AD, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "CARE-009",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the nutritional management approach for ALS patients.",
      "response": "\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-010",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe neurostimulation therapy for ALS and the evidence supporting its use.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research.\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been identified in the study,\n\n\n,\nthe study,\n\n,\n,\n,\n,\nand the study,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-011",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the investigation of lithium as a potential ALS treatment and the clinical evidence.",
      "response": "\n\n\n\nThe study, we have been identified in the disease. The most common genetic mutations in the disease, and FTD, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-012",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the detailed presynaptic mechanism by which riluzole reduces glutamate excitotoxicity.",
      "response": "\n\n\n\n\n\n\n\n\n, we investigated the role of the potential therapeutic potential therapeutic potential in the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the use of the first study, we investigated the role of the potential for the importance of the potential in the potential of the potential therapeutic strategy for the potential for the potential for the need to the potential of the potential for the development of the treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the use of the potential of the context of the study, we investigated the importance of the role in the potential of the potential of the potential therapeutic strategy for the potential for the need to evaluate the potential of the potential of the potential of the potential.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the use of the potential for the potential of the potential of the potential of the importance of the role in the development of the treatment, we have a comprehensive research.\n\n\n\n\n\n\n\n\nthe study, we investigated the need to evaluate the limitations of the importance of the importance of the potential therapeutic strategy for the use of the importance of the potential of the potential of the need for the importance of the potential in the development of the treatment.\n\n\nand the need to explore the role of the potential of the potential therapeutic strategies, and clinical trials.\n\n\n\n\n\n\n\n, we have a comprehensive research on the use of the field, and the study.\n\n\n\n\n\nThe study,\nthe comprehensive studies,\n,\n,\n,\nand the first-based approaches for the use of the use of the development, and clinical trials.\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-013",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the recommended dosage and administration schedule for riluzole in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-014",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the rationale and clinical evidence for memantine in ALS treatment.",
      "response": "\n\n\n\n\n\n\n, we have a common genetic and disease.\n\n\n, we investigated the role of the disease progression of the disease.\n\n\n\n, we found that the most common mutations in the disease. We also identified a rare diseases, we have a common mechanisms, we have a common genetic subtypes, we have been reported that are known to be associated with ALS.\n\n\nand the disease, we have a role in the disease progression of the disease.\n\n, we have a recent study, we found that the most common genetic and FTD, we have a rare neurodegenerative diseases, we identified in AD pathology, and tau pathology, and tau pathology. We investigated the molecular mechanisms of tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\nand tau pathology, we have a role in AD, we identified a role of tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-015",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Trace the FDA regulatory timeline for AMX0035 (Relyvrio) from the CENTAUR trial through its withdrawal.",
      "response": "\n\n\n\n\n\n\nThe study, we used the first study, we performed using a model. The data were conducted using the data. The data collection, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the data from the data analysis was performed using the data, we used for the data, we used the data, we used the data, we conducted using the data. The data, we set the data, we used the data, we used the data collection, we used the data, we used the data, we used the data.\n\n\n\n\n\n\n\n\n\n\n\nThe data were performed using the data from the data, we used the data, we conducted using the data, we set using a model was performed using the data, we used to assess the data. The data, we first study, we used the data, we used the data, we used the data, we used the data, we used the data, we used the data, we used the data, we conducted using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe data, we performed the data, we first study, we used the data from the data, we set the data were obtained from the data, we used the data, we used the data, we used to assess the data. The data, we conducted using the data, we used the data, we used the model, we used the data, we performed the data, we review, we first study, we used the data, we set the data, we used the data from the data, we analyzed the data.\n\n\n\nthe data, we used the data, we conducted using the data, we used the data, we used the data, we used the data, we performed the data, we first study, we used the data, we used the data and the data, we used the data, we used the data. The data, we identified a comprehensive data from the data, we conducted using the data, we used for the data, we used the data.\n\n\n\n\n\n\n\n\n\n\n\n\nthe data, we performed the data, we used the data, we used the data, we used the data, we used the data, we identified a comprehensive data, we used the data, we will be available in the data.\n\n\n\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-016",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe how edaravone is administered to ALS patients and any changes to its delivery method.",
      "response": "\n\n\n\n\nThe study, we have a common in the disease progression of the disease. The most common genetic mutations in the disease progression of the disease.\n\n\n\n\nand the most common genetic variants in the most common mutations in the most common in the most common mutations in the most common in the disease.\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a rare diseases, we have been identified a common and the disease.\n\nThe most common genetic mutations in the most common genetic variants of the most common gene expression in the RNA-binding protein, which are known to be associated with the RNA-associated proteins, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, and RNA-binding protein, which are known as a common RNA-binding protein.\n\n\nand the RNA-binding protein, we identified a single-specific RNA-binding protein, and RNA-binding protein (Figure 5). The RNA-binding protein in the RNA-binding protein-binding protein, we found that the RNA-binding protein-binding protein-binding protein (Figure 5). We also show that the RNA-binding protein-binding protein-binding protein-binding protein-binding protein.\n\n\nand the RNA-binding protein-binding protein-binding protein in the RNA-binding protein and RNA-binding protein, which is a protein-binding protein-binding protein-binding protein (Figure 5). The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we found that the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5). The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we found that the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-017",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the detailed molecular mechanism of edaravone's antioxidant action in ALS.",
      "response": "\n\n\n\n\n\n\n, we have a common in the most common and the most common mechanisms of the disease.\n\n\n\n\nThe most common genetic mutations in the most common proteins, we identified in the most common proteins, which are known to be associated with the most common proteins that are essential for the development of the disease.\n\n\n\n\n\nand the most common pathways, we have a common mechanisms, we have been identified a role in the disease. The most common mutations in the disease progression of the disease and the disease.\n\n\n\n\n\n\n, we investigated the molecular modifications that the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the accumulation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation. The most common proteins in the aggregation, we have a role in the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the accumulation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation.\n\n\n\n\nand the most common proteins, we have a role in the molecular modifications, we identified a crucial for the development of the aggregation of the disease progression and the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the accumulation of the aggregation of the aggregation. We investigated the molecular mechanisms that the most common proteins, we have been identified in the cellular homeostasis, which are essential for the formation of the development of the aggregation.\n\n\n\n\nand the most common proteins, we have a role in the disease progression of the disease.\n\n\n\n\nand the most common mechanisms, we have a common proteins that the most common proteins, we have been identified in the most common proteins, which are known to be associated with the aggregation of the aggregation of the aggregation of the aggregation of the accumulation of the aggregation of the aggregation of the aggregation of the aggregation.\n\n\n\nand the most common proteins, we have a complex, and the protein, which is the RNA-binding protein (Figure 5). The RNA-associated proteins, which are also known to the RNA-binding protein, which are essential for the RNA-binding proteins, which are the RNA-binding proteins. We found that the RNA-binding proteins in the RNA-binding proteins,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-018",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the drugs used to treat muscle cramps in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n*\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 1,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-019",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the clinical investigation of celecoxib for ALS and its outcomes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n, we investigated the study, we identified in the study, we have been reported that the disease progression.\n\n\n\n, we found that the most common genetic variants in the disease. We also be associated with a rare diseases, we have a role of ALS.\n\n, we have a recent study, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-020",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe cortexilin's neuroprotective mechanism and its clinical evidence in ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "GENE-011",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the OPTN (optineurin) gene and its role in ALS pathogenesis.",
      "response": "\n\n\nThe most common mutations in the most common variants in the aggregation of the accumulation of the nucleus, which are known to the development of the disease.\n\n\n\n\n\n\nand the most common mutations in the most common mutations in the most common proteins that are essential for the most common in the most common proteins, and the most common proteins, such as well as a common proteins, and the aggregation, and the most common proteins, which are known to be associated with the disease.\n\n\n\n\n\nand the most common proteins, the most common mutations in the most common proteins, and the most common proteins, and the most common proteins, and the most common proteins, such as well as a common proteins, and the aggregation of the aggregation, and the most common proteins, which are known to be associated with the aggregation.\n\n\n\n\n\n\nand the most common proteins that are essential for the most common proteins, such as the aggregation, such as the aggregation of the aggregation, and the aggregation of the aggregation, and the aggregation, and the aggregation, and the aggregation, and the aggregation, which are known to be associated with the aggregation.\n\n\n\n\nand the most common proteins that are essential for the protein, and the aggregation, and the aggregation, and the aggregation, and the aggregation, which are also known as a complex, which is the RNA-binding proteins, and RNA-binding proteins, which are essential for the RNA-binding proteins.\n\n\nand the RNA-associated proteins, which can be used to the RNA-binding protein, which are essential for the RNA-binding proteins, which are essential for RNA-binding proteins, which are known as a crucial for RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins.\n\nand the RNA-binding proteins that can be used to the RNA-binding protein aggregation of RNA-binding proteins, which are essential for RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins.\nand the RNA-binding proteins, which can be a protein-binding proteins, which is a crucial for RNA-binding proteins, which are essential for the RNA-binding proteins, which are known as a complex, which are essential for RNA-binding proteins, which are essential for RNA-binding proteins, and RNA-binding proteins.",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-012",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of NEK1 in ALS and how it was identified as a risk gene.",
      "response": "\n\n\nThe most common mutations in the most common mutations in the disease, which is a common to be associated with the disease.\n\n\n\n\n\n\n\n\n\n\n\n\nand the most common genetic variants in the most common mutations in the most common mutations in the most common mutations in the disease.\n\n\n\n\n\n\n\n\n\nThe most common mutations in the most common mutations, we have a rare diseases, we have been identified in the most common mutations in the disease.\n\n\n\n\nand the most common genetic variants of the most common mutations in the most common genes, we have a common mutations in the disease. We have a common variant in the most common gene expression of the RNA-binding protein and RNA-associated proteins, which are known to be associated with the RNA-binding protein.\n\n\nand the RNA-binding protein (43) is a protein.\n\n\n\n\n\n\nThe RNA-binding protein that the RNA-binding protein in the RNA-binding protein, we found that the RNA-binding protein and RNA-binding protein (Figure 5). The RNA-associated TDP-43 aggregation of TDP-43, we investigated the TDP-43 pathology in the TDP-43 aggregation of TDP-43 aggregation.\n\nand TDP-43 aggregation of TDP-43, we identified a TDP-43 aggregation of TDP-43 aggregation of TDP-43 aggregation and TDP-43, TDP-43 aggregation of TDP-43, TDP-43, TDP-43, TDP-43 pathology in the TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43 aggregation of TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-013",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the C9orf72 repeat expansion including the repeat unit, normal vs pathogenic repeat counts, and inheritance.",
      "response": " The second-old controls, and the same of the most common than the time.\n\n\n\n\n\nThe first study was performed using the first study. The study, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we identified a comprehensive analysis of the data, we conducted the data from the data, we performed the data, we performed using the data. We performed the data, we analyzed the data, we used the data, we used the data, we used the data, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we identified a comprehensive studies, we conducted the model of the first study, we performed the data from the data, we used the data, we used the data, we used the data, we used the data. We have a comprehensive analysis of the data, we used the data, we used the data, we used the data, we identified a comprehensive data, we conducted the data, we used the study, we performed the data from the data, we used the data, we used the data, we used the model, we used the data.\n\n\n\n\n\n\n\n\n\n\nthe analysis of the data, we have a comprehensive data, we identified a comprehensive studies and the data, we conducted the study, we performed the data, we used the data, we used for the data, we used the data, we used the data from the data. We will be available the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe dataset, we have a comprehensive studies, we have a comprehensive analysis of the study, we identified a comprehensive data, we have a comprehensive data, we have a comprehensive data.\n\n\n\nand the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\n\n\n\nthe\n\n\n\nThe data, we will be performed using the study, we will be used to evaluate the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the data from the data\n\n\n\n\n\n\n\n\n\n\n\n\nthe data\n\n\nThe data\n\n\nWe have a comprehensive study, we will be used to evaluate the data.\n\n\n\n\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-014",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe VCP mutations and their role in ALS and inclusion body myopathy with Paget disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "GENE-015",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Discuss the genetic contributions to sporadic ALS cases.",
      "response": "\n\n\n\n\n\n\n\n\n\n, we have a role in the disease.\n\n, we investigated the most common genetic and the disease progression of the disease. We have been identified a rare diseases, we have a common mechanisms that the disease, and FTD, and FTD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-016",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe SQSTM1/p62 and its connection to ALS pathogenesis.",
      "response": "\n\n\n\n\nThe most common in the most common mutations in the disease, and FTD, and tau pathology, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, tau, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-017",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe UBQLN2 mutations and their pathological consequences in ALS.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression. We have a common genetic changes in the disease. The most common genetic variants in the disease progression of the disease.\n\n\n\n\n\n\n\nThe most common genetic mutations in the disease, we identified a rare neurodegenerative diseases, we have been reported that the disease.\n\nand the disease, we have a role in the disease, we found that the disease, we have a common genetic and FTD, we investigated the disease progression of the disease. We have a recent study, we have a novel insights into the disease.\n",
      "tokens_generated": 124,
      "is_coherent": true
    },
    {
      "question_id": "GENE-018",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain the role and timing of genetic counseling for ALS patients and their families.",
      "response": "\n\n\n\n\n\nThe study, we have a recent study, we identified a comprehensive research that the need to be available in this study.\n\n\n\n\n\n\n\n\n, we have been developed a comprehensive studies, we have a comprehensive research on the clinical trials, we will be used for future research.\n\n\n",
      "tokens_generated": 70,
      "is_coherent": true
    },
    {
      "question_id": "GENE-019",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe ATXN2 intermediate repeat expansions and their role as an ALS risk factor.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "GENE-020",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the MNDF1 gene, its protein product, and the ALS clinical presentation caused by MNDF1 mutations.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-011",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List and describe the upper motor neuron (UMN) signs that clinicians evaluate when diagnosing ALS.",
      "response": "\n\n\n\n\nThe study, we have a comprehensive research on the clinical trials.\n\n\n\n\n\nThe study, we have been identified by the study, we have a comprehensive data from the study. We have a single-based approach for the first study, and the study, and the study, and the study, and the study, and the study, and the study, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\nThe study, we have been identified in this study, we have a comprehensive research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials. The study, we have been developed the data, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\n",
      "tokens_generated": 267,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-012",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the electromyographic findings that support ALS diagnosis, including both spontaneous and motor unit changes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-013",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the key clinical and diagnostic differences between cervical myelopathy and ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-014",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe multifocal motor neuropathy (MMN) and explain why differentiating it from ALS is clinically important.",
      "response": "\n\n\nThe most common in the most common genetic mutations in the disease, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-015",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain why MRI is performed during the ALS diagnostic workup and what findings are expected.",
      "response": "\n\n\n\nThe study, we have a comprehensive research that the study of the first study, we have been identified in the clinical trials. The study, we have been reported that the study, we have a single-based approach for the study, we have a comprehensive studies.\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive research on the study, we have a comprehensive and clinical trials, we have a comprehensive research. The study, we have been identified in the study, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\nand the study, we used a comprehensive research, we have developed a comprehensive research that the study, we will be available in the study.\n",
      "tokens_generated": 153,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-016",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe primary lateral sclerosis (PLS) and explain how it is distinguished from ALS.",
      "response": "\n\nThe study, we have a recent study, we found that the disease progression of the disease. The study, we investigated the clinical trials, we have been identified in the clinical trials. We have a comprehensive research on the study, we have been developed to identify the future research.\n\n",
      "tokens_generated": 61,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-017",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the body regions that diagnostic criteria use to classify the extent of ALS spread.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a single-based sequencing (ALS) and RNA-binding protein in the RNA-43, which is a common RNA-binding protein-binding protein. The RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-018",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare the Gold Coast criteria to the El Escorial and Awaji criteria and explain what the Gold Coast criteria simplified.",
      "response": "\n\n\nThe study, we have been reported that the importance of the use of the impact on the development of the patient. The study, we have a comprehensive research is needed to be available in the study.\n\n\n\n\n\n\nThe study, we have a systematic review, we have a recent study, we have a study, we have a study, we have been identified a comprehensive studies, we have a comprehensive research that the study, we have a comprehensive research on the study, and clinical trials, we have a comprehensive research. The study, we have a comprehensive research is a comprehensive research, we have been developed a comprehensive understanding of the data from the study, and to evaluate the importance of the need for future research.\n\n\n\n\nThe study, we will be available in this study, we will be used to identify the study, we will be available, we will be available in the study, we will be available in the study, we have a comprehensive studies.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we will be available, we will be available, we will be used to evaluate the data, we will be considered for the study, we will be available, we will be available in this study, we have a comprehensive research.\n\n\n",
      "tokens_generated": 273,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-019",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe progressive muscular atrophy (PMA) and its relationship to the ALS spectrum.",
      "response": "\n\n\n\nThe study, we investigated the first-based approach for the potential in the need for the importance of the development of the future research.\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have been developed a comprehensive and clinical trials, we will be available to identify the use of the understanding of ALS.\n",
      "tokens_generated": 81,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-020",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the Brinkworth ALS staging system and how it classifies disease progression.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-011",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the dexpramipexole Phase 3 trial for ALS and the reasons for its failure.",
      "response": "\n\n\nThe study, we used a comprehensive research on the clinical trials. The study, we have been identified in this study, we have been developed a comprehensive research. We have a comprehensive studies, we have a comprehensive research, we have been identified a comprehensive research.\n\n\n\n\n",
      "tokens_generated": 61,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-012",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the investigation of ceftriaxone for ALS treatment and the results of the clinical trial.",
      "response": "\n\n\n\nThe study, we identified a comprehensive research that the current studies, we have been reported that the importance of the role in the development of the disease progression.\n\n\n\n\n\n\n\n\nand recent study, we investigated the study, we have a comprehensive research on the potential of the clinical trials.\n\n\n\nThe study, we have identified a comprehensive research and clinical trials, we have been developed a comprehensive research.\n\n\n",
      "tokens_generated": 95,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-013",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain why the ALSFRS-R is the dominant primary endpoint in ALS trials and what its limitations are.",
      "response": "\n\n\nThe study, we have a recent study, we have a comprehensive research that the clinical trials for the study. The study, we have been identified a comprehensive research on the study. We have a comprehensive studies, we have a comprehensive research, we have a comprehensive research, we have a comprehensive and clinical trials, we have been developed a comprehensive understanding of ALS.\n\n",
      "tokens_generated": 78,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-014",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the minocycline clinical trial for ALS and explain the surprising outcome.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-015",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the ATLAS trial of tofersen and its significance for presymptomatic ALS carriers.",
      "response": "\n\n\n\n\n\n, we have been reported that the disease progression in the disease. The most common genetic mutations in the disease.\n\n\n\n\n, we identified a rare neurodegenerative diseases, we have a common genetic and disease. We have a rare neurodegenerative disease, we found that the disease-43, we observed that the most common variant in the disease.\n\n\n\n\n\nand the most common genetic variants of the disease, we have been reported in the disease.\n\n\n\n\n\n\nThe most common mutations in the most common genetic mutations in the most common genetic mutations in the disease, we identified in the disease-specific TDP-43 pathology, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-016",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how biomarkers are used to select and stratify patients in contemporary ALS clinical trials.",
      "response": "\n\n\n\n\nThe study, we have a comprehensive research on the need for AD.\n\n\n\n\n\nand the use of AD, we have been identified a common genetic and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, tau, tau pathology, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-017",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the NCT08442197 clinical trial of neurogenix for ALS, including the study design and primary results.",
      "response": "\n\n\n\n\n\n\n\nThe study, we have been identified in the study. The study, we investigated the study, we have a comprehensive research that the study, we have been developed a comprehensive studies.\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been identified a comprehensive understanding of the study, we have been used to identify the importance of ALS.\n\n\nThe study, we have a comprehensive research on the study, we have been identified in the study, we have been developed a comprehensive and clinical trials.\n\n\n\n\n\n\n\n, we have a systematic review, we have a comprehensive research that the study, we have a comprehensive research, we have been identified in this study, we have a comprehensive studies, we have a comprehensive research on the study, we have a comprehensive research. The study, we have a comprehensive understanding of ALS and clinical trials, we have been developed a comprehensive research.\n\n",
      "tokens_generated": 199,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-018",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the key obstacles to recruiting and retaining patients in ALS clinical trials.",
      "response": "\n\n\n\n\n\n\n\n, we have been identified a common genetic and disease progression. The study, we investigated the role of the disease progression of the disease progression.\n\n\n\n\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n\nand the disease, we found that the disease, we have a rare neurodegenerative diseases, we have been identified a common genetic and disease, with ALS. We have a common genetic and FTD, we have a common genetic and FTD, and AD, and tau pathology, and tau pathology, and tau pathology in AD, and tau pathology, and tau, and tau pathology, and tau pathology, and tau, and tau, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau pathology.\n\nand tau, we identified a common tau pathology, we have been reported that the aggregation of tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau pathology, and tau, and tau pathology.\nand tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-019",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the gene therapy strategies currently in clinical trials for ALS.",
      "response": "\n\n\n\n\n\n\n, we have been identified a common genetic and genetic and disease progression.\n\n\n\n\n\n, we investigated the role of the development of the disease.\n\n\n\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n, we have a rare neurodegenerative diseases, we have a common mechanisms, and disease, and disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, and tau pathology, tau, tau, and tau, tau, and tau, and tau, tau, and tau, tau, tau, tau, tau, and tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-020",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the BENEFIT-ALS platform trial design and its contributions to ALS trial methodology.",
      "response": "\n\n\n\nThe study, we conducted a comprehensive research on the clinical trials. The study, we have been identified in this study, we have been developed a comprehensive studies.\n\n\n\n\n\nand the study, we used the study, we have a comprehensive data from the study, we will be available for the data.\n\n\n\n\nThe study, we have been published, we have been reported that the first study, we have a comprehensive research, we have a comprehensive studies, we have been identified in the study, we have been developed a comprehensive and clinical trials, we have a comprehensive research.\n\n\n",
      "tokens_generated": 130,
      "is_coherent": true
    },
    {
      "question_id": "MECH-011",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the non-cell-autonomous toxicity of astrocytes in ALS and the key experimental evidence.",
      "response": "\n\n\n, we investigated the role of the potential for the development of the importance of the development of the development of ALS. We have shown that the most common mechanisms of the disease progression of the disease progression of ALS.\n\n\n\n\n\n\nand the most common genetic mutations in the disease and ALS.\n\n\n\n, we investigated the role in the molecular mechanisms, we identified a novel therapeutic potential of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the disease.\n\n\n\n\n\nand the disease progression of ALS, we have been identified in the disease and disease. We have a common genetic mutations in the most common mechanisms that are known to be associated with the disease.\n\n\n, we have a recent study, we have a novel molecular mechanisms, we have a role in the development of the disease.\nand the disease, we have a rare diseases, we have been identified a comprehensive research on the disease and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\nThe study, we have demonstrated that the importance of ALS.\n\n, we have a role in the development of AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD.\nand the most common mechanisms of AD, we have been identified a promising therapeutic potential for AD.\n\n\n\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-012",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe stress granules and their connection to ALS disease mechanisms.",
      "response": "\n\n\n\n\n, we investigated the role of ALS.\n\n\n\n\n\n, we have a role in the disease progression of the disease.\n\nand the disease, we found that the disease progression of the disease progression of the disease.\n\n\n\n, we have a common genetic and FTD, we identified a rare neurodegenerative diseases, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology. We found that the tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation of tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau, tau pathology, tau pathology, and tau pathology, tau, tau, tau, tau, tau, tau, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-013",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the role of nuclear pore complex (NPC) defects in ALS and the evidence linking them to C9orf72 disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nALS\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "MECH-014",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how defects in axonal transport contribute to ALS pathology.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression and disease. We have a role in the disease progression of the disease, we found that the disease progression of the disease.\n\n\n\n\nThe disease is a common mechanisms underlying mechanisms for the pathogenesis of the development of the disease.\n\n\n\n\nand the disease is a rare neurodegenerative diseases, we have a common and disease, we investigated the disease.\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the disease, we have been identified in the disease, we have a common genetic mutations in the disease progression of the disease.\nand the disease, we have a rare neurodegenerative diseases, we have a common genetic and disease, we have a common mechanisms that are known to be associated with ALS.\n, we have a rare neurodegenerative disease, we have been identified in the disease, we have a common genetic mutations in the disease.\n\n, we have a common mutations in the disease, we investigated the disease, we have a common genetic and FTD, we have a common genetic and FTD, we have a common tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\nand tau pathology, we identified a role of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-015",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the mitochondrial abnormalities found in ALS motor neurons and their pathological consequences.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the disease progression of the disease. We have a common mechanisms that the pathogenesis of the disease.\n\n\n\n\n\nand the most common mutations in the disease, we have been identified in the disease.\n\n\n\n, we have a rare neurodegenerative diseases, we have a common genetic and FTD, we have a common pathological dysfunction, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau aggregation of tau pathology in AD, and tau pathology.\n, we investigated the most common mechanisms underlying tau pathology, we identified in AD pathology, we have been reported that are known to be associated with AD.\n\nand tau pathology, we found that tau pathology, tau pathology, tau pathology, tau pathology, tau, tau aggregation, tau, tau, and tau pathology, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-016",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the prion-like spreading mechanism proposed for ALS protein aggregates.",
      "response": "\n\n\n\n\n\n, we investigated the potential of the role in the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the disease.\n\n\n\n\n\n\n\n\n\n\n, we have a common mechanisms that the role in the most common genetic and disease progression of ALS.\n\nand the most common mutations in the disease, we have been identified in the disease. We have a rare neurodegenerative diseases, we have a common mutations in the disease, we have a common disease.\n\n\n\n\n\n\n, we investigated the disease, we have a role of the disease progression and disease, we have a common genetic changes in the disease.\n\n\nand the disease, we identified a common mechanisms that the disease-associated TDP-43 aggregation of TDP-43 pathology, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-017",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how microglial cells contribute to ALS motor neuron damage.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression and disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we identified a role in the disease, we have been reported that the disease progression of the disease.\nand the disease is a common mutations in the disease.\n\n\n\n, we found that the most common TDP-43 aggregation of TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-018",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe dipeptide repeat proteins produced by C9orf72 repeat expansions and their mechanisms of toxicity.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a rare diseases, we have been reported that the role in the context of the importance of the disease.\n\n\n\n\n, we investigated the role of the role in the role in the role in the role in the development of the role in the disease progression of the disease.\n\n\nand the role in the role in the role in the role in the disease progression of the disease, we have a common genetic and disease.\n\n\n, we have been identified a rare neurodegenerative diseases, we have a common mechanisms, we have a crucial for the disease.\n\n\n\n\n\n, we have a novel biomarkers that the molecular mechanisms underlying mechanisms, we have been identified in the development of the pathogenesis of the disease progression, and disease.\nand the most common genetic mutations in the disease, we have been identified, we have been identified in the disease, and FTD, and tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, tau pathology, tau, tau pathology.\nand tau, we investigated the molecular mechanisms of tau pathology, we have a role in AD, and tau pathology, and tau pathology, and tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, tau pathology, and tau pathology, and tau pathology, tau pathology, tau pathology.\nand tau pathology, we investigated the aggregation of tau pathology, we have been identified in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology.\nand the",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-019",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain the excitotoxicity hypothesis in ALS and the evidence supporting it.",
      "response": "\n\n\n\n\nThe role of the development of the development of the development of the disease progression, and disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a common mechanisms that the disease.\nand the most common mutations in the disease progression of the disease.\n\n\n\n\n, we have been identified a rare diseases, we have a common genetic and disease, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-020",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the CREB4 signaling cascade and its proposed neuroprotective role at the neuromuscular junction in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-011",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the major ALS genes in the order they were discovered, with approximate dates.",
      "response": "\n\n\n\nThe authors have a single-based approach for the first study. The study, we used the data from the model of the first study. We identified a comprehensive studies, we performed the data, we conducted using the data, we used the data.\n\n\n\n\n\n\n\n\n\nand the study, we used the data, we have a single-based approach for the data, we will be used to evaluate the model.\n\n\n\n\n\n\n\n\nthe first study, we have been identified in the data, we have a comprehensive studies, we have a comprehensive research on the data, we have a comprehensive and clinical trials, we have a comprehensive data, we have a comprehensive data.\n",
      "tokens_generated": 151,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-012",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the year the C9orf72 GGGGCC repeat expansion was identified and name the research groups involved.",
      "response": "\n\n\n\n\nThe study, we used the first study, we conducted a comprehensive data. The data were performed using the data from the data, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the data, we identified a single-based approach for the data, we have developed a single-based and the data. We used the data, we used the data, we performed using the data from the data. The study, we used the data, we used the data, we used the data, we used the data, we used the data, we identified a comprehensive studies, we used to identify the data.\n\n\n\n\n\n\n\n\n\n\n\n\nThe data, we have a single-based approach for the data from the data, we performed using the data, we used the data, we used the data and the data, we used the data, we identified a comprehensive data, we used to identify the data. We conducted a comprehensive studies, we used the data, we used the data, we have a single-based sequencing.\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe dataset, we performed using the data, we used the data from the data, we identified a comprehensive data, we used for the data, we used the data, we used the data, we used the data, we have a single-based sequencing. We used the data, we used the data, we used to identify the data and the data.\n\n\n\n\n\n\n\n\n\n\n\n\nthe dataset, we identified a comprehensive data, we performed using the data, we used the data, we used for each sample size of the first-based sequencing. We have a single-seq data from the data, we used to identify the model and the data. The study, we used the data, we used the data, we used the data, we identified a comprehensive analysis, we performed using the dataset, we used the data.\n\n\n\n\n\n\n\n\n\nthe dataset, we used the data, we used for each sample size of the first-based sequencing and the data, we used to identify the model. We have a single-based sequencing data, we identified a single-based sequencing. The study, we used the data, we performed using the data, we used the data.\n\n\n\n\n\n\n\n\nthe\n\n\n\nThe dataset\n\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-013",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "List the major ALS diagnostic criteria systems in chronological order with their years of publication.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the first study, we have a significant differences in the disease progression.\n\n\n, we found that the most common genetic and the clinical trials, we have been identified in the disease.\n\n\n\n, we have a recent study, we have a rare neurodegenerative diseases, we have a common genetic diagnosis of the disease. We have a common genetic mutations in the disease, we have a significant differences in the disease progression, and FTD, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, and tau, and tau, tau, tau, tau, and tau, and tau, and tau, tau, tau, and tau pathology, tau, and tau, tau, tau, and tau, tau, and tau, and tau, tau, tau, tau, tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-014",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when TDP-43 was identified in ALS pathology and explain the significance of this discovery.",
      "response": "\n\n\n\nThe study, we found that the disease progression of the disease progression in the disease. The study, we have a significant correlation between the disease progression of the disease. We also reported that the most common genetic changes in the disease.\n\n\n\n\n\nand the first study, we identified a significant differences in the disease and FTD patients with AD pathology in AD, and tau pathology, and tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, tau, tau, tau pathology.\n\n\nand tau pathology, we found that tau pathology in AD, we identified a significant correlation between the tau pathology in AD patients with AD pathology in AD pathology in AD pathology in AD. We found that the AD, we have been reported that the tau pathology in AD and tau pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau pathology, tau pathology, tau, tau, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-015",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State when the Ice Bucket Challenge took place and its fundraising impact for ALS research.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-016",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "List all FDA-approved ALS-specific therapies in the order they were approved, with dates.",
      "response": "\n\n\nThe study of the study, we have a comprehensive studies, we have been identified in the study. The study, we have a single-based approach for the study, and clinical trials, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 59,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-017",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when the SOD1 transgenic mouse model for ALS was created and by whom.",
      "response": "\n\n\n\n\n\n\nThe study, we used a comprehensive research that we identified in the clinical trials. We have been reported that the current studies, we have a comprehensive research on the clinical trials.\n",
      "tokens_generated": 44,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-018",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year tofersen (Qalsody) received FDA approval and the type of approval granted.",
      "response": "\n\n\n\n\nThe study, we used to assess the model. The data collection, we conducted a comprehensive analysis, we used the data from the data, we performed the data, we used the data. We have a comprehensive data, we identified a comprehensive data, we used the data, we used the data, we used the data, we used the data, we used to evaluate the model.\n\n\n\nThe study, we conducted the data, we used the data, we performed the data, we used the data, we have a comprehensive data from the data, we identified a comprehensive analysis of the data, we will be available data. We will be used for the data, we will be used to evaluate the data.\n\n\n\n\n\n\n\nThe study, we will be conducted using the data, we will be performed in the data, we have been described by the data from the data, we will be used to assess the data, we will be available on the data. We will be used for the data, we will be used to evaluate the data, we will be used to identify the data, we will be used to determine the data, we will be performed using a comprehensive information, we have a comprehensive and the data.\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 267,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-019",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when FUS gene mutations were discovered in ALS and describe the significance.",
      "response": "\n\n\n\n, we have a role in the disease progression of the disease. We found that the most common genetic changes in the disease. The results in the disease, we identified a recent study, we investigated the disease-specific TDP-43, we observed that TDP-43, we found that TDP-43 and TDP-43 pathology in the TDP-43 aggregation of TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-020",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Determine whether the C9orf72 hexanucleotide repeat expansion was identified as a cause of ALS in 2006.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-011",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Compare ALS incidence rates across Europe, Asia, and the Americas.",
      "response": "\n\n\n\n\n\n\n\nThe study of the study, we have been reported that the role in the importance of the development of the impact on the context of the treatment.\n\n\n\n\n\n\n\n\nand the study is a recent study, we have a comprehensive research, we have been identified in this study. The study, we have been developed a comprehensive studies, we have been reported that the study, we have been identified in the study, we have been identified in the study, we have been identified in the study.\n\n\n\n\n\nThe study, we have been identified a recent study, we have a systematic review, we have been identified a comprehensive research, we have been developed a comprehensive studies, we have been reported that the study, we have a comprehensive research and the study, we have a comprehensive research in this study.\n\n\n\n\n\nThe study, we have a comprehensive research, we have a recent study, we have a systematic review, we have a comprehensive research, we have a comprehensive studies, we have been identified a comprehensive research that the study, we have a comprehensive research and clinical trials, we have a comprehensive research.\n\n\n\n\n",
      "tokens_generated": 247,
      "is_coherent": true
    },
    {
      "question_id": "EPI-012",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence for increased ALS risk among military veterans beyond the Gulf War.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-013",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the frequency and spectrum of cognitive changes in ALS patients.",
      "response": "\n\n\n\n, we investigated the study, we have a disease progression of the disease.\n\n\n\n\n\n\n\n, we found that the most common genetic mutations in the disease. We also identified a role in the disease-43, we observed in the disease and FTD pathology in AD pathology in the tau pathology in AD. The most common tau pathology in AD pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-014",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare survival statistics and prognosis between bulbar-onset and limb-onset ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-015",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how age relates to ALS risk and what the peak incidence age range is.",
      "response": "\n\n\nThe study, we investigated the study, we used a comprehensive research that the study. We have a comprehensive studies, we have a comprehensive research on the study, we identified a comprehensive research that the study, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research.\n\n\n",
      "tokens_generated": 87,
      "is_coherent": true
    },
    {
      "question_id": "EPI-016",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the environmental and occupational risk factors that epidemiological studies have associated with ALS.",
      "response": "\n\n\n\nThe study, we identified a comprehensive research, we identified a common genetic testing of the first study. The study, we used the study, we identified a single-based clinical trials, we will be available in the study.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive studies, we have been reported that the study of the study, we have a significant correlation between the first study. The study, we identified a single-based clinical trials, we have a comprehensive research, we have a comprehensive and clinical trials, we have a comprehensive research. We have a comprehensive studies, we have a comprehensive data from the study, we have been developed a comprehensive research.\n",
      "tokens_generated": 156,
      "is_coherent": true
    },
    {
      "question_id": "EPI-017",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the historically documented ALS high-incidence clusters in the Western Pacific region.",
      "response": "\n\n\n\n\n\n\n\n\n\n, we investigated the first study, we have a role of the impact on the importance of the potential for the role in the role in the role in the role in the role in the role in the context of the role in the development of the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the impact on the importance.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have a role of the first study, we have been reported that the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the context of the impact on the importance of the role in the role in the role in the role in the role in the role in the role in the role in the role in the development.\n\n\n\n\n\n\n\n\n\nand the role in the role in the role in the role in the role in the context of the impact of the role in the importance of the role in the study, we have a role in the first study, we present study, we have been reported that the role in the role in the role in the role in the role in the role in the role in the development of the role in the role in the context of the impact on the role in the importance of the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the role in the development.\n\n\n\n\n\n\n\n\n\n\nand the study, we have a role of the first study, we present study, we have been reported that the importance of the role in the role in the role in the context of the impact on the role in the role in the role in the role in the role in the role in the role in the role in the role in the development of the role in the role in the role in the role in the role in the role in the importance of the role in the role in the role in the context of the impact on the use of the role in the role in the role in the role in the role in the context of the role in the role in the development.\n\n\n\n\n\n\n\n\n\nThe study, we have a role in the",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-018",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the sex ratio in ALS incidence and describe how it varies by disease type.",
      "response": "\n\n\n\nThe study, we have a significant differences between the disease. We found that the most common genetic changes in the disease progression of the disease. The results suggest that the role in the role in the disease progression of the disease progression in the disease progression of the disease progression and the disease.\n\n\n\n\n\nand the disease is a rare neurodegenerative diseases, we have a common genetic mutations in the disease. We found that the most common genetic mutations in the disease, we have a common genetic mutations in the disease. The disease, we have a common genetic mutations in the disease, we identified a common genetic variants of the disease progression and FTD, with AD pathology, and tau, and tau aggregation, and tau, and tau pathology, and tau pathology, and tau, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-019",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the major ALS population-based registries and their contribution to epidemiological knowledge.",
      "response": "\n\n\n\n\n\nThe study, we have a comprehensive research on the clinical trials. The study, we have been identified in this study, we have been developed a comprehensive studies, we have a comprehensive research. We have demonstrated that the importance of the limitations, we have been reported that the future research.\n\n\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive research on the study, we have identified a comprehensive research and clinical trials, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive research, we have been developed a comprehensive research, we have a comprehensive understanding of the data, we have a comprehensive research.\n\n",
      "tokens_generated": 146,
      "is_coherent": true
    },
    {
      "question_id": "EPI-020",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological findings on ALS risk among Italian professional soccer players and state the incidence rate.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-011",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the multidisciplinary clinic model for ALS care and the evidence supporting its benefit.",
      "response": "\n\n\n\n\n\nThe study, we identified a comprehensive research on the study, we have been developed in the need to be available.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a systematic review, we have a comprehensive and clinical trials for the study, we have identified in the study, and clinical trials.\n\nThe study, we have been developed a comprehensive research on the literature.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we used the study, we have a comprehensive research on the study, we will be available for the data.\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have been identified in the study, we have developed a comprehensive and clinical trials, we have a comprehensive studies, we have been published, we have a comprehensive research.\n\n\n\n\n\nand the study, we have a comprehensive data from the study, we have a comprehensive research on the study, we will be available for the data collection, we have in the study, we have been developed a comprehensive and to evaluate the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have identified a comprehensive studies, we have a comprehensive research, we have a comprehensive research on the study, we will be available for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been developed a comprehensive research and the data from the data, we have identified in the data, we have a comprehensive studies, we will be used to evaluate the data.\n\n\n\n\nthe study, we have been published in the study, we have a comprehensive research on the study, we will be available for the data, we will be developed in the data.\n\n",
      "tokens_generated": 400,
      "is_coherent": true
    },
    {
      "question_id": "CARE-012",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the assistive communication technologies available for ALS patients who lose the ability to speak.",
      "response": "\n\n\n\n\nThe study, we conducted a comprehensive research on the clinical trials. The study, we have been identified in the study, and clinical trials, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\n\n\n, we used the study, we have a comprehensive studies, we have a comprehensive research. We have a comprehensive research, we have a comprehensive research on the study, we will be available for ALS.\n\n",
      "tokens_generated": 95,
      "is_coherent": true
    },
    {
      "question_id": "CARE-013",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the advance care planning issues that are particularly important for ALS patients.",
      "response": "\n\n\n\n\n, we have a common mechanisms of ALS.\n\n, we investigated the role in the importance of ALS.\n\n\n\nand the role in the disease progression and the development of the pathogenesis of ALS.\n\n\n\nThe most common genetic mutations in the disease.\n\n\n\n\n, we identified a rare diseases, we have been reported that the disease.\n, we have also known to be associated with ALS.\n, we have a rare neurodegenerative diseases, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "CARE-014",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the methods and timing for monitoring respiratory function in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-015",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the cognitive-behavioral symptoms in ALS-FTD and the management approaches for patients and caregivers.",
      "response": "\n\n\n\nThe study, we have been identified a comprehensive research. The study, we have a recent study, we have been reported that the clinical trials, we have been developed a comprehensive research on the importance of the development of the future research.\n\n\n\n\n\n",
      "tokens_generated": 58,
      "is_coherent": true
    },
    {
      "question_id": "CARE-016",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the physical and psychological burden on ALS caregivers and available support resources.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-017",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the contributions of speech-language pathologists to ALS patient care.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-018",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe when and how hospice and palliative care services are integrated into ALS management.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-019",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the types of pain experienced by ALS patients and the pharmacological approaches to management.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-020",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the MotorGuard protocol for respiratory support in ALS patients, including its evidence base.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    }
  ]
}